Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 57Carcinoma, Non-Small-Cell Lung 46Ovarian Neoplasms 31Stomach Neoplasms 22Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Lung Neoplasms 18Neoplasm Metastasis 17Fallopian Tube Neoplasms 14Triple Negative Breast Neoplasms 13Esophageal Neoplasms 13Esophageal Squamous Cell Carcinoma 10Colorectal Neoplasms 9Carcinoma, Ovarian Epithelial 9Melanoma 8Head and Neck Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Carcinoma, Renal Cell 6Adenocarcinoma of Lung 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Solid Tumors 5Testicular Neoplasms 4Testicular Germ Cell Tumor 4Recurrence 4Carcinoma, Transitional Cell 4

Interventions

Gemcitabine 3Irinotecan 2Albumin-Bound Paclitaxel 2ibrutinib 1adavosertib 1Paclitaxel 1PEGPH20 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic Pancreatic Adenocarcinoma × Paclitaxel × Clear all
NCT02562898 2021-05-06

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

University of California, San Francisco

Phase 1/2 Completed
18 enrolled 15 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡